RU2016134406A - Композиции апилимода и способы их применения - Google Patents

Композиции апилимода и способы их применения Download PDF

Info

Publication number
RU2016134406A
RU2016134406A RU2016134406A RU2016134406A RU2016134406A RU 2016134406 A RU2016134406 A RU 2016134406A RU 2016134406 A RU2016134406 A RU 2016134406A RU 2016134406 A RU2016134406 A RU 2016134406A RU 2016134406 A RU2016134406 A RU 2016134406A
Authority
RU
Russia
Prior art keywords
apilimod
composition
additional active
agents
cell lymphoma
Prior art date
Application number
RU2016134406A
Other languages
English (en)
Russian (ru)
Other versions
RU2016134406A3 (OSRAM
Inventor
Хенри ЛИХЕНШТЕЙН
Джонатан М. РОТБЕРГ
София ГЕЙЛ
Нил БИХАРРИ
Пол БЕКЕТТ
Шон ЛАНДРЕТТЕ
Крис КОНРАД
Мэтт ДАЙЕР
Тянь СЮЙ
Original Assignee
Лэм Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лэм Терапьютикс, Инк. filed Critical Лэм Терапьютикс, Инк.
Publication of RU2016134406A publication Critical patent/RU2016134406A/ru
Publication of RU2016134406A3 publication Critical patent/RU2016134406A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2016134406A 2014-01-24 2015-01-23 Композиции апилимода и способы их применения RU2016134406A (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461931078P 2014-01-24 2014-01-24
US201461931075P 2014-01-24 2014-01-24
US61/931,078 2014-01-24
US61/931,075 2014-01-24
US201462077127P 2014-11-07 2014-11-07
US62/077,127 2014-11-07
PCT/US2015/012733 WO2015112888A1 (en) 2014-01-24 2015-01-23 Apilimod compositions and methods for using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2019107011A Division RU2019107011A (ru) 2014-01-24 2015-01-23 Композиции апилимода и способы их применения

Publications (2)

Publication Number Publication Date
RU2016134406A true RU2016134406A (ru) 2018-03-01
RU2016134406A3 RU2016134406A3 (OSRAM) 2018-09-20

Family

ID=53681989

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2019107011A RU2019107011A (ru) 2014-01-24 2015-01-23 Композиции апилимода и способы их применения
RU2016134406A RU2016134406A (ru) 2014-01-24 2015-01-23 Композиции апилимода и способы их применения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2019107011A RU2019107011A (ru) 2014-01-24 2015-01-23 Композиции апилимода и способы их применения

Country Status (12)

Country Link
US (3) US10179135B2 (OSRAM)
EP (1) EP3096757B1 (OSRAM)
JP (2) JP6855243B2 (OSRAM)
KR (1) KR102320190B1 (OSRAM)
CN (1) CN106659716B (OSRAM)
AU (1) AU2015209133B2 (OSRAM)
BR (1) BR112016017112A2 (OSRAM)
CA (1) CA2937655C (OSRAM)
IL (1) IL246879B (OSRAM)
MX (1) MX373818B (OSRAM)
RU (2) RU2019107011A (OSRAM)
WO (1) WO2015112888A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2937655C (en) 2014-01-24 2022-06-28 Lam Therapeutics, Inc. Apilimod compositions for cancer treatment
AU2015342863B2 (en) * 2014-11-07 2021-01-21 AI Therapeutics, Inc. Apilimod for use in the treatment of melanoma
US10206910B2 (en) * 2014-11-07 2019-02-19 Lam Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
WO2016118709A1 (en) * 2015-01-23 2016-07-28 Lam Therapeutics, Inc. Anti-viral compositions containing pikfyve inhibitors and use thereof
WO2016160102A1 (en) * 2015-03-31 2016-10-06 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
TWI746449B (zh) * 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
JP2019502707A (ja) * 2016-01-21 2019-01-31 ラム・セラピューティクス，インコーポレーテッド 癌をアピリモドで処置するためのバイオマーカー
KR20180015441A (ko) 2016-08-03 2018-02-13 엘지전자 주식회사 롤리 키보드
CN109952113A (zh) * 2016-08-25 2019-06-28 人工智能治疗公司 包含pikfyve抑制剂的组合物和与rank信号传导的抑制相关的方法
RU2020130837A (ru) 2018-02-21 2022-03-21 ЭйАй ТЕРАПЬЮТИКС, ИНК. Комбинационная терапия апилимодом и глутаматергическими агентами
CN108743947B (zh) * 2018-07-04 2020-12-15 复旦大学附属肿瘤医院 一种治疗b细胞淋巴瘤的药物组合物
CN110496128B (zh) * 2019-09-23 2022-09-30 吉林大学 利培酮或帕潘立酮在制备治疗弥漫性大b细胞淋巴瘤的药物中的应用
AU2021207804A1 (en) 2020-01-13 2022-09-01 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
CN117529324A (zh) * 2021-06-11 2024-02-06 奥夫艾治疗公司 稳定的阿匹莫德组合物和其用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
CA2176348C (en) 1993-11-12 2004-11-02 Sanjay Tyagi Hybridization probes for nucleic acid detection, universal stems, methods and kits
US6693097B2 (en) 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
EA009873B1 (ru) 2004-02-06 2008-04-28 Элан Фармасьютикалз, Инк. Способ ингибирования роста опухоли и/или метастатического прогрессирования
TWI380816B (zh) 2004-04-13 2013-01-01 Synta Pharmaceuticals Corp 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑
US7829708B2 (en) * 2004-09-08 2010-11-09 Chelsea Therapeutics, Inc. Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation
US7923557B2 (en) 2004-11-10 2011-04-12 Synta Pharmaceuticals Corporation Process for preparing trisubstituted pyrimidine compounds
TW200720256A (en) 2005-05-13 2007-06-01 Synta Pharmaceuticals Corp IL-12 modulatory compounds
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
AU2006316605B2 (en) 2005-11-17 2012-04-26 Osi Pharmaceuticals, Inc. Fused bicyclic mTOR inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US7659274B2 (en) 2006-01-25 2010-02-09 Osi Pharmaceuticals, Inc. Unsaturated mTOR inhibitors
AR061980A1 (es) 2006-07-12 2008-08-10 Univ Tennessee Res Foundation Acilanilidas sustituidas y metodos para su utilizacion
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
EP2118087B1 (en) 2007-02-06 2012-03-28 Novartis AG Pi 3-kinase inhibitors and methods of their use
RU2438664C2 (ru) 2007-05-15 2012-01-10 Пирамал Лайф Сайнсиз Лимитед Синергическая фармацевтическая комбинация для лечения рака
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5258331B2 (ja) * 2008-03-03 2013-08-07 ロート製薬株式会社 光安定性が改善されたニューキノロン系抗菌剤含有医薬組成物
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
ES2661367T3 (es) * 2010-03-08 2018-03-28 Sloan Kettering Institute For Cancer Research Inhibidores de cinasa CDC7 y sus usos
WO2011122620A1 (ja) 2010-03-29 2011-10-06 味の素株式会社 フェニルアラニン誘導体を含有する医薬製剤
US8402515B2 (en) 2010-05-06 2013-03-19 Jonathan Weizman Apparatus and method for establishing a peer-to-peer communication session with a client device
WO2011146727A1 (en) * 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
TR201815010T4 (tr) * 2010-11-19 2018-11-21 Ecole Polytechnique Fed Lausanne Epfl 2-piperazin-1-yl-4h-1,3-benzotiazin-4-one türevleri ve bunların, memeli enfeksiyonlarının tedavisinde kullanımı.
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2873402C (en) 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
EP2903644A4 (en) 2012-10-05 2016-03-09 Cerulean Pharma Inc TREATMENT OF CANCER
US9295731B2 (en) 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
CA2937655C (en) 2014-01-24 2022-06-28 Lam Therapeutics, Inc. Apilimod compositions for cancer treatment
AU2015342863B2 (en) 2014-11-07 2021-01-21 AI Therapeutics, Inc. Apilimod for use in the treatment of melanoma
US10206910B2 (en) 2014-11-07 2019-02-19 Lam Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
EP3253389A4 (en) 2015-02-03 2018-07-18 LAM Therapeutics, Inc. Apilimod compositions and methods for using same
WO2016160102A1 (en) 2015-03-31 2016-10-06 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
TWI746449B (zh) 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
WO2020009971A1 (en) 2018-07-05 2020-01-09 Mayo Foundation For Medical Education And Research Pikfyve inhibitors
WO2021051135A1 (en) 2019-09-12 2021-03-18 AI Therapeutics, Inc. Pikfyve inhibitors for cancer therapy

Also Published As

Publication number Publication date
JP2017503842A (ja) 2017-02-02
EP3096757A1 (en) 2016-11-30
MX2016009590A (es) 2017-05-09
US20190183902A1 (en) 2019-06-20
IL246879B (en) 2020-05-31
EP3096757B1 (en) 2020-10-21
KR102320190B1 (ko) 2021-11-03
CN106659716A8 (zh) 2017-06-30
US11266654B2 (en) 2022-03-08
RU2016134406A3 (OSRAM) 2018-09-20
KR20160126984A (ko) 2016-11-02
CN106659716A (zh) 2017-05-10
BR112016017112A2 (pt) 2017-08-08
US20170007613A1 (en) 2017-01-12
MX373818B (es) 2020-03-24
CA2937655C (en) 2022-06-28
RU2019107011A (ru) 2019-04-08
IL246879A0 (en) 2016-08-31
WO2015112888A1 (en) 2015-07-30
EP3096757A4 (en) 2017-10-04
US20200268764A1 (en) 2020-08-27
CA2937655A1 (en) 2015-07-30
NZ722491A (en) 2021-01-29
JP6855243B2 (ja) 2021-04-07
US10179135B2 (en) 2019-01-15
AU2015209133B2 (en) 2019-10-03
CN106659716B (zh) 2021-03-12
AU2015209133A1 (en) 2016-08-11
JP2021046430A (ja) 2021-03-25

Similar Documents

Publication Publication Date Title
RU2016134406A (ru) Композиции апилимода и способы их применения
IL292438B1 (en) Small molecule inhibitors of kras g12c mutant
JP2017503842A5 (OSRAM)
JP2020505433A5 (OSRAM)
RU2010118448A (ru) Комбинированная терапия антителами анти-cd20 типа ii в сочетании с активным агентом анти-bcl-2
NZ723271A (en) Fused imidazole derivatives useful as ido inhibitors
EA201591932A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ
WO2007084670A8 (en) Specific therapy using integrin ligands for treating cancer
JP2016539134A5 (OSRAM)
WO2020102804A3 (en) Pharmaceutical combination for treatment of cancer
WO2004096224A3 (en) Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
HRP20220718T1 (hr) Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka
RU2008138560A (ru) Улучшенные способы лечения опухолей
RU2015118135A (ru) Содержащие заместители бензольные соединения
MX2024012131A (es) Composicion farmaceutica, uso de la misma y metodo para tratar el cancer
WO2008087025A3 (en) Specific therapy and medicament using integrin ligands for treating cancer
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
BR112015009559A2 (pt) uso de composto antissenso na preparação de medicamento para tratamento de cãncer, composto antissenso e composição farmacêutica
JP2018525358A5 (OSRAM)
WO2018102687A3 (en) Combination therapy for treating cancer
RU2018105923A (ru) Способы лечения рака с использованием апилимода
BR0206046A (pt) Usos de uma combinação e de sapogenina protopanaxadiol ou sapogenina protopanaxatriol, e, composição farmacêutica
RU2017119065A (ru) Апилимод для применения в лечении рака почек
JP2018503610A5 (OSRAM)
RU2007130991A (ru) Составы, обладающие антиканцерогенными свойствами

Legal Events

Date Code Title Description
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20200316